Jazz Pharma accused of pay-for-delay deals over Xyrem
14-10-2021
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Michael Vi / Shutterstock.com
Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem (sodium oxybate).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Xyrem, Jazz Pharmaceuticals, Avadel, big pharma
